AstraZeneca Pharma India — 360° view

AstraZeneca Pharma India, a company in the Pharmaceuticals industry, reported revenue of ₹729 crore and net profit of ₹62 crore for the September 2026 quarter.

AstraZeneca Pharma India (NSE: ASTRAZEN) closed at ₹6,167.50 on 20 Nov 2026, down 32.5% over the past year. Its market capitalisation is ₹15,419 crore and it trades at 81.9 times earnings.

Share price
₹6,167.50 (20 Nov 2026)
Market cap
₹15,419 Cr (20 Nov 2026)
P/E
81.92 (20 Nov 2026)
Revenue
₹729 Cr (September 2026 quarter)
Net profit
₹62 Cr (September 2026 quarter)
ROCE
29.3% (FY26)
ROE
23.3% (FY26)
Book value
₹352 (FY26)
Dividend yield
0.58% (last 12 months to 20 Nov 2026)
52-week high / low
₹9,264.00 / ₹5,640.00 (20 Nov 2026)
1-year return
-32.5% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: ASTRAZEN

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.